



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2016





HIV/AIDS Drug Treatment Program

Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

October 2016

N = 7146



Health Authority	Male	Female	All
FRASER	1360	392	1752
INTERIOR	365	98	463
NORTHERN	138	77	215
VANCOUVER COASTAL	3373	452	3825
VANCOUVER ISLAND	705	159	864
	5941	1178	7119
		Unknown/not stated:	27
		Total:	7146

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2011 - October 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2011 - October 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (October 2011 - October 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (October 2011 - October 2016)






1.6 Percent Distribution of Active Participants by CD4 Count (October 2011 - October 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count (October 2011 - October 2016)






1.8 Active and Inactive Participants (October 2011 - October 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2011 - October 2016)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2011 - October 2016)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(October 2011 - October 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT
(October 2011 - October 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2011 - October 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2011 - October 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(October 2011 - October 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2011 - October 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(October 2011 - October 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (October 2011 - October 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(October 2011 - October 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (October 2011 - October 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2011 - October 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	4	810	5	<40	3
1988	24	7	0	7	7	570	7	<40	3
1989	23	54	2	56	48	525	55	<40	3
1990	22	61	1	62	59	550	61	<40	3
1991	22	37	3	40	30	530	37	<40	3
1992	22	69	6	75	60	595	72	<40	3
1993	21	146	15	161	142	550	154	<40	3
1994	20	95	14	109	91	560	103	<40	3
1995	20	127	24	151	126	540	144	<40	3
1996	18	369	60	429	373	600	410	<40	3
1997	16	298	38	336	295	650	318	<40	3
1998	15	216	45	261	221	570	247	<40	3
1999	15	181	42	223	197	570	211	<40	3
2000	15	143	38	181	158	600	173	<40	3
2001	15	132	39	171	148	555	160	<40	3
2002	14	140	30	170	151	550	166	<40	3
2003	13	174	32	206	185	590	201	<40	3
2004	12	181	41	222	191	590	210	<40	3
2005	11	202	48	250	211	620	231	<40	3
2006	10	206	45	251	205	590	234	<40	3
2007	9	278	55	333	291	600	313	<40	3
2008	8	301	71	372	316	630	352	<40	3
2009	7	343	77	420	360	630	407	<40	3
2010	6	309	73	382	330	625	357	<40	3
2011	5	364	77	441	378	660	413	<40	3
2012	4	299	65	364	316	685	348	<40	3
2013	3	286	70	356	298	640	344	<40	3
2014	2	312	58	370	304	695	351	<40	3
2015	1	336	55	391	339	632	373	<40	3
2016	0	272	54	326	298	535	308	<40	3
Total:		5943	1178	7121					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6739	760	2430	<40	2189	580
FEB-2015	6787	754	1976	<40	1779	580
MAR-2015	6834	748	2172	<40	1972	570
APR-2015	6845	739	2150	<40	1971	580
MAY-2015	6881	740	2032	<40	1842	560
JUN-2015	6897	740	2253	<40	2043	580
JUL-2015	6924	739	2036	<40	1853	580
AUG-2015	6922	752	2075	<40	1831	580
SEP-2015	6922	749	2265	<40	2059	580
OCT-2015	6957	740	2100	<40	1878	590
NOV-2015	7008	722	2064	<40	1875	580
DEC-2015	6988	725	2015	<40	1830	600
JAN-2016	6974	737	2264	<40	2020	590
FEB-2016	6993	735	2067	<40	1866	590
MAR-2016	6998	737	2155	<40	1956	590
APR-2016	7017	734	2053	<40	1863	580
MAY-2016	7045	747	2071	<40	1877	590
JUN-2016	7065	739	2178	<40	1982	610
JUL-2016	7057	752	1949	<40	1750	600
AUG-2016	7072	751	2065	<40	1831	600
SEP-2016	7115	752	2217	<40	1947	600
OCT-2016	7146	747	2157	<40	1827	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1513	2042	104	1325	89	340
FEB-2015	1497	2111	103	75	89	380
MAR-2015	1469	2260	101	56	95	410
APR-2015	1475	2244	83	2239	73	460
MAY-2015	1460	2339	73	148	65	380
JUN-2015	1477	2263	96	106	92	420
JUL-2015	1470	2326	71	598	60	380
AUG-2015	1480	2303	82	2341	77	440
SEP-2015	1504	2231	91	128	86	370
OCT-2015	1486	2347	81	<40	70	405
NOV-2015	1463	2458	85	169	78	400
DEC-2015	1500	2312	79	344	64	330
JAN-2016	1512	2286	114	<40	102	470
FEB-2016	1504	2348	80	751	71	380
MAR-2016	1512	2315	87	130	83	440
APR-2016	1516	2310	87	<50	73	360
MAY-2016	1502	2388	78	<40	68	350
JUN-2016	1512	2380	71	65	55	510
JUL-2016	1536	2325	82	74	76	440
AUG-2016	1563	2223	96	118	80	370
SEP-2016	1547	2299	93	231	77	400
OCT-2016	1526	2444	69	56	65	420

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6706	1513	13	24	149	188	-35	11954
FEB-2015	6756	1497	7	36	187	163	50	12006
MAR-2015	6809	1469	7	29	177	144	53	12046
APR-2015	6808	1475	15	28	168	172	-1	12082
MAY-2015	6846	1460	9	33	170	150	38	12123
JUN-2015	6869	1477	5	36	153	159	23	12170
JUL-2015	6905	1470	5	25	167	149	36	12208
AUG-2015	6903	1480	7	19	145	156	-2	12238
SEP-2015	6898	1504	9	32	157	180	-5	12279
OCT-2015	6926	1486	14	24	171	147	28	12316
NOV-2015	6977	1463	9	29	183	150	51	12357
DEC-2015	6954	1500	11	21	153	182	-23	12389
JAN-2016	6944	1512	9	16	154	168	-10	12410
FEB-2016	6964	1504	5	18	177	162	20	12438
MAR-2016	6971	1512	9	24	168	172	7	12472
APR-2016	6991	1516	6	20	166	157	20	12506
MAY-2016	7020	1502	7	23	159	144	29	12537
JUN-2016	7035	1512	12	34	162	165	15	12580
JUL-2016	7025	1536	10	25	134	154	-10	12612
AUG-2016	7041	1563	10	40	164	173	16	12672
SEP-2016	7091	1547	5	27	183	149	50	12715
OCT-2016	7121	1526	10	22	161	140	30	12746

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	47	6296	435	67	6845	0.69%	91.98%	6.36%	0.98%	100.00%
MAY-2015	49	6334	431	68	6882	0.71%	92.04%	6.26%	0.99%	100.00%
JUN-2015	51	6329	446	72	6898	0.74%	91.75%	6.47%	1.04%	100.00%
JUL-2015	46	6359	453	67	6925	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	49	6359	444	70	6922	0.71%	91.87%	6.41%	1.01%	100.00%
SEP-2015	49	6370	439	64	6922	0.71%	92.03%	6.34%	0.92%	100.00%
OCT-2015	52	6399	442	64	6957	0.75%	91.98%	6.35%	0.92%	100.00%
NOV-2015	57	6439	445	67	7008	0.81%	91.88%	6.35%	0.96%	100.00%
DEC-2015	53	6425	448	62	6988	0.76%	91.94%	6.41%	0.89%	100.00%
JAN-2016	55	6410	448	61	6974	0.79%	91.91%	6.42%	0.87%	100.00%
FEB-2016	58	6439	437	59	6993	0.83%	92.08%	6.25%	0.84%	100.00%
MAR-2016	54	6445	438	61	6998	0.77%	92.10%	6.26%	0.87%	100.00%
APR-2016	54	6464	442	57	7017	0.77%	92.12%	6.30%	0.81%	100.00%
MAY-2016	57	6495	439	54	7045	0.81%	92.19%	6.23%	0.77%	100.00%
JUN-2016	60	6502	447	56	7065	0.85%	92.03%	6.33%	0.79%	100.00%
JUL-2016	57	6501	442	57	7057	0.81%	92.12%	6.26%	0.81%	100.00%
AUG-2016	57	6512	447	56	7072	0.81%	92.08%	6.32%	0.79%	100.00%
SEP-2016	58	6552	448	57	7115	0.82%	92.09%	6.30%	0.80%	100.00%
OCT-2016	58	6584	447	57	7146	0.81%	92.14%	6.26%	0.80%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		emtricitabine		tenofovir <TAF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2583 40%	10 29%	2220 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3846 59%	0 0%	0 0%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3878 59%	0 0%	0 0%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3913 59%	0 0%	0 0%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3911 59%	0 0%	0 0%
MAY-2015	8 20%	2638 40%	7 18%	2280 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3922 59%	0 0%	0 0%
JUN-2015	10 21%	2633 39%	10 21%	2287 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3941 59%	0 0%	0 0%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3944 59%	0 0%	0 0%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3941 59%	0 0%	0 0%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3911 58%	0 0%	0 0%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3901 58%	0 0%	0 0%
NOV-2015	17 41%	2785 41%	15 37%	2440 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3910 58%	0 0%	0 0%
DEC-2015	5 16%	2793 41%	5 16%	2454 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	27 84%	3883 57%	0 0%	0 0%
JAN-2016	4 19%	2819 42%	4 19%	2486 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3852 57%	0 0%	0 0%
FEB-2016	10 36%	2854 42%	9 32%	2522 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3830 57%	0 0%	0 0%
MAR-2016	9 26%	2878 43%	7 21%	2543 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3811 56%	0 0%	0 0%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	22 65%	3815 56%	0 0%	5 0%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	23 74%	3836 56%	0 0%	6 0%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	32 74%	3832 56%	1 2%	9 0%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	23 72%	3835 56%	0 0%	9 0%
AUG-2016	11 19%	2936 43%	11 19%	2627 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	48 81%	3834 56%	6 10%	22 0%
SEP-2016	14 33%	2970 43%	12 28%	2661 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	29 67%	3852 56%	3 7%	25 0%
OCT-2016	11 35%	2996 43%	11 35%	2689 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	20 65%	3856 56%	0 0%	26 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	tenofovir <TDF>			
	Initial		All	
JAN-2015	25	71%	4210	64%
FEB-2015	44	85%	4241	64%
MAR-2015	30	75%	4269	64%
APR-2015	24	69%	4267	64%
MAY-2015	33	83%	4276	64%
JUN-2015	37	79%	4292	64%
JUL-2015	34	89%	4294	64%
AUG-2015	18	60%	4281	64%
SEP-2015	24	59%	4251	63%
OCT-2015	27	73%	4239	63%
NOV-2015	25	61%	4242	63%
DEC-2015	27	84%	4208	62%
JAN-2016	17	81%	4169	62%
FEB-2016	18	64%	4137	61%
MAR-2016	26	76%	4114	61%
APR-2016	22	65%	4107	61%
MAY-2016	23	74%	4122	61%
JUN-2016	31	72%	4120	60%
JUL-2016	23	72%	4118	60%
AUG-2016	42	71%	4100	60%
SEP-2016	27	63%	4108	60%
OCT-2016	20	65%	4107	59%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2029 60%	6 50%	930 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2029 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	970 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 1%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	988 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	1999 59%	6 38%	1018 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1965 58%	10 56%	1037 31%	0 0%	358 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1957 58%	11 79%	1050 31%	1 7%	351 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1054 31%	3 27%	345 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1912 58%	11 69%	1060 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1087 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	4 27%	1875 56%	9 60%	1107 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1838 56%	8 67%	1118 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1130 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1157 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1198 37%	0 0%	294 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1221 38%	0 0%	283 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1237 38%	0 0%	284 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1690 53%	11 79%	1243 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1664 52%	26 90%	1256 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1645 52%	9 82%	1272 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1619 51%	9 82%	1267 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1083 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1074 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	2 100%	1055 42%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	997 41%	0 0%	307 13%	1 25%	854 35%	1 25%	258 11%
APR-2016	3 33%	991 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	970 41%	1 25%	299 13%	2 50%	837 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	296 13%	0 0%	831 35%	2 29%	261 11%
SEP-2016	2 50%	952 41%	0 0%	295 13%	0 0%	820 35%	2 50%	264 11%
OCT-2016	1 20%	947 41%	2 40%	300 13%	1 20%	815 35%	1 20%	268 12%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	540 30%	4 22%	348 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	575 31%	8 33%	354 19%	0 0%	73 4%	2 8%	879 48%	0 0%	1 0%
MAR-2015	9 50%	599 32%	5 28%	367 20%	0 0%	69 4%	4 22%	868 47%	0 0%	2 0%
APR-2015	7 50%	627 33%	4 29%	373 20%	2 14%	67 4%	1 7%	861 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	380 20%	1 6%	70 4%	2 12%	863 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	394 20%	0 0%	72 4%	4 15%	875 44%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	781 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	847 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	889 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	438 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	988 43%	10 45%	445 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1021 44%	4 36%	461 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1063 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1116 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1154 47%	4 22%	492 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1183 47%	4 24%	494 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	518 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1304 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1411 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2388	34.89	2095	30.61	1237	18.07	184	2.69	67	0.98	874	12.77
MAY-2015	2392	34.76	2094	30.43	1274	18.51	179	2.60	68	0.99	875	12.71
JUN-2015	2363	34.26	2078	30.12	1321	19.15	172	2.49	72	1.04	892	12.93
JUL-2015	2370	34.22	2068	29.86	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2365	34.17	2044	29.53	1381	19.95	168	2.43	70	1.01	894	12.92
SEP-2015	2323	33.56	2032	29.36	1444	20.86	168	2.43	64	0.92	891	12.87
OCT-2015	2325	33.42	2005	28.82	1491	21.43	167	2.40	64	0.92	905	13.01
NOV-2015	2315	33.03	2012	28.71	1540	21.97	160	2.28	67	0.96	914	13.04
DEC-2015	2288	32.74	1982	28.36	1580	22.61	161	2.30	62	0.89	915	13.09
JAN-2016	2286	32.78	1944	27.87	1612	23.11	158	2.27	61	0.87	913	13.09
FEB-2016	2280	32.60	1925	27.53	1669	23.87	153	2.19	59	0.84	907	12.97
MAR-2016	2266	32.38	1905	27.22	1707	24.39	154	2.20	61	0.87	905	12.93
APR-2016	2244	31.98	1895	27.01	1756	25.02	154	2.19	57	0.81	911	12.98
MAY-2016	2256	32.02	1887	26.78	1781	25.28	157	2.23	54	0.77	910	12.92
JUN-2016	2258	31.96	1877	26.57	1811	25.63	152	2.15	56	0.79	911	12.89
JUL-2016	2227	31.56	1867	26.46	1848	26.19	150	2.13	57	0.81	908	12.87
AUG-2016	2213	31.29	1840	26.02	1913	27.05	142	2.01	56	0.79	908	12.84
SEP-2016	2195	30.85	1834	25.78	1977	27.79	144	2.02	57	0.80	908	12.76
OCT-2016	2175	30.44	1831	25.62	2032	28.44	146	2.04	57	0.80	905	12.66

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	24	4	2	3	4	9	450
NOV-2015	29	5	1	6	5	10	370
DEC-2015	21	1	3	4	5	7	375
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	23	2	1	3	4	13	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10390	2658
FEB-2015	10436	2665
MAR-2015	10475	2674
APR-2015	10495	2686
MAY-2015	10549	2710
JUN-2015	10635	2757
JUL-2015	10704	2805
AUG-2015	10770	2861
SEP-2015	10855	2916
OCT-2015	10907	2956
NOV-2015	10970	2996
DEC-2015	11016	3024
JAN-2016	11050	3054
FEB-2016	11143	3135
MAR-2016	11203	3183
APR-2016	11249	3216
MAY-2016	11308	3265
JUN-2016	11364	3296
JUL-2016	11409	3331
AUG-2016	11454	3337
SEP-2016	11481	3341
OCT-2016	11523	3372

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
October 2016

N = 7146

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	34	47	22
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	71	93	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	331	436	254	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	19	19	14
	35-49	55	63	40
	50+	96	145	80
Total HSDA:	175	232	134	
Total HA:		611	808	463

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	52	53	*
	35-49	174	202	*
	50+	376	544	*
Total HA:		611	808	463

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	477	643	365
Female	134	165	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	463	53	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	5	*
	<5 years	11	*
	Total HSDA:	34	22
KOOTENAY BOUNDARY	10 years or more	37	26
	5 years or more	19	16
	<5 years	15	11
	Total HSDA:	71	53
OKANAGAN	10 years or more	176	125
	5 years or more	73	59
	<5 years	82	70
	Total HSDA:	331	254
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	88	61
	5 years or more	44	37
	<5 years	43	36
	Total HSDA:	175	134
Total HA:		611	463

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	319	223
5 years or more	141	116
<5 years	151	124
Total HA:	611	463

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	53	13	22
KOOTENAY BOUNDARY	63	112	23	39
OKANAGAN	195	685	61	248
THOMPSON/CARIBOO/SHUSWAP	126	424	37	107
Total:	420	1274	134	416

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	95

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	26	27	21
	35-49	108	120	82
	50+	181	245	149
	Total HSDA:	321	398	257
FRASER NORTH	0-19	18	18	5
	20-34	105	106	83
	35-49	357	404	264
	50+	485	753	398
	Total HSDA:	965	1281	750
FRASER SOUTH	0-19	10	10	7
	20-34	100	102	73
	35-49	362	416	301
	50+	440	647	364
	Total HSDA:	912	1175	745
Total HA:		2198	2854	1752

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	34	34	17
	20-34	231	235	177
	35-49	827	940	647
	50+	1106	1645	911
Total HA:		2198	2854	1752

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1670	2197	1360
Female	528	657	392

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1752	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	157	118
	5 years or more	90	79
	<5 years	74	60
	Total HSDA:	321	257
FRASER NORTH	10 years or more	471	346
	5 years or more	252	208
	<5 years	242	196
	Total HSDA:	965	750
FRASER SOUTH	10 years or more	423	333
	5 years or more	252	208
	<5 years	237	204
	Total HSDA:	912	745
Total HA:		2198	1752

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1051	797
	5 years or more	594	495
	<5 years	553	460
Total HA:		2198	1752

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	129	413	42	80
FRASER NORTH	231	1433	62	263
FRASER SOUTH	201	1197	41	335
Total:	561	3043	145	678

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	183
FRASER NORTH	621
FRASER SOUTH	505
Total:	1309

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	67
	50+	*	*	186
	Total HSDA:		319	455
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		157	202
VANCOUVER	0-19	51	54	7
	20-34	412	421	318
	35-49	1540	1770	1141
	50+	2520	4190	1957
	Total HSDA:	4523	6435	3423
Total HA:		4999	7092	3825

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	57	60	8
	20-34	461	471	358
	35-49	1667	1915	1245
	50+	2814	4646	2214
Total HA:		4999	7092	3825

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4392	6230	3373
Female	605	860	452

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3825	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	170	140
	5 years or more	67	61
	<5 years	82	71
	Total HSDA:	319	272
RICHMOND	10 years or more	70	55
	5 years or more	39	32
	<5 years	48	43
	Total HSDA:	157	130
VANCOUVER	10 years or more	2329	1670
	5 years or more	1195	921
	<5 years	999	832
	Never on ART	0	0
	Total HSDA:	4523	3423
Total HA:	4999	3825	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2569	1865
5 years or more	1301	1014
<5 years	1129	946
Never on ART	0	0
Total HA:	4999	3825

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	145	374	56	100
RICHMOND	42	265	13	94
VANCOUVER	547	10019	208	5311
Total:	734	10658	277	5505

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	99

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		286	400
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		111	146
SOUTH VANCOUVER ISLAND	0-19	7	7	*
	20-34	53	55	*
	35-49	211	246	*
	50+	406	631	*
	Total HSDA:		677	939
Total HA:		1074	1485	864

Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
0-19	11	11	5
20-34	86	91	65
35-49	335	383	270
50+	642	1000	524
Total HA:	1074	1485	864

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	870	1205	705
Female	204	280	159

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	864	52	480	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	138	113
	5 years or more	63	54
	<5 years	85	70
	Total HSDA:	286	237
NORTH VANCOUVER ISLAND	10 years or more	52	42
	5 years or more	28	24
	<5 years	31	26
	Total HSDA:	111	92
SOUTH VANCOUVER ISLAND	10 years or more	347	245
	5 years or more	162	136
	<5 years	168	154
	Total HSDA:	677	535
Total HA:		1074	864

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	537	400
	5 years or more	253	214
	<5 years	284	250
Total HA:		1074	864

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	176	758	84	213
NORTH VANCOUVER ISLAND	121	242	44	69
SOUTH VANCOUVER ISLAND	188	1571	51	530
Total:	485	2571	179	812

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	33
SOUTH VANCOUVER ISLAND	92
Total:	169

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		42	50
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	22
	50+	*	*	23
	Total HSDA:		69	101
NORTHERN INTERIOR	0-19	7	7	*
	20-34	25	27	*
	35-49	75	93	*
	50+	78	126	*
	Total HSDA:		185	253
Total HA:		296	404	215

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	38	45	*
	35-49	116	147	*
	50+	133	203	*
Total HA:		296	404	215

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	180	250	138
Female	116	154	77

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	215	49	550	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	14	7
	5 years or more	17	11
	<5 years	11	10
	Total HSDA:	42	28
NORTH WEST	10 years or more	18	8
	5 years or more	33	29
	<5 years	18	14
	Total HSDA:	69	51
NORTHERN INTERIOR	10 years or more	57	33
	5 years or more	52	43
	<5 years	76	60
	Total HSDA:	185	136
Total HA:		296	215

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	89	48
	5 years or more	102	83
	<5 years	105	84
Total HA:		296	215

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	9	11
NORTH WEST	66	146	21	29
NORTHERN INTERIOR	102	406	20	178
Total:	201	611	50	218

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	12
NORTHERN INTERIOR	17
Total:	36

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	39	*
	Total HA:	49	85	36
FRASER	FRASER EAST	31	39	28
	FRASER NORTH	60	91	46
	FRASER SOUTH	75	104	62
	Total HA:	166	234	136
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	44	20
	RICHMOND	7	12	6
	VANCOUVER	504	793	411
	Total HA:	534	849	437
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	77	42
	NORTH VANCOUVER ISLAND	12	21	11
	SOUTH VANCOUVER ISLAND	35	72	28
	Total HA:	99	170	81
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	35	58	30
	NORTHERN INTERIOR	64	96	51
	Total HA:	108	165	88
Total:		956	1503	778

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	597	959	478
Female	359	544	300

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	778	49	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

